Context Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Context Therapeutics Inc. filed a Form 8-K regarding a Nasdaq listing-compliance matter. The earliest reported event occurred on January 24, 2023; the filing was signed on January 27, 2023. The company’s common stock trades on Nasdaq under the symbol CNTX.
Financial and Operating Metrics
The filing does not provide revenue, profitability, cash flow, margin, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
Nasdaq notified the company that its common stock had failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice did not immediately affect the listing or trading of the shares.
Outlook, Risks, and Contingencies
- The company received an initial 180-calendar-day compliance period ending July 24, 2023.
- Compliance may be restored if the stock closes at or above $1.00 per share for at least 10 consecutive business days before the deadline, subject to Nasdaq’s notification.
- If compliance is not restored by July 24, 2023, the company may be eligible for an additional 180-day grace period.
- The company stated that it will monitor the closing bid price and evaluate available options to regain compliance.
- There is no assurance that the company will regain compliance, obtain a second compliance period, or satisfy other Nasdaq listing requirements.
Important Facts for Investors to Verify
- Whether CNTX regained compliance with the $1.00 minimum bid-price requirement by the applicable deadline.
- Whether Nasdaq granted any additional compliance period or took further delisting-related action.
- Whether the company used measures such as a reverse stock split or other corporate action to address the bid-price deficiency.
- Whether the company continued to satisfy all other Nasdaq listing requirements.